Abstract
The role of elevated triglyceride (TG) levels in the pathogenesis of atherosclerosis is controversial. Some studies suggest that TG might play a direct role in the development of vascular disease. Elevated TG levels are also associated with other vascular risk factors and may therefore represent an indirect marker of a high risk state. Another issue is that laboratory measurements of TG levels frequently show a substantial variability. Accumulating epidemiological data show that there is an independent association of TG levels with vascular risk. Some interventional studies also suggested that lowering TG levels might prevent vascular events. It appears that TG might be more important as therapeutic targets against a background of optimal low density lipoprotein cholesterol (LDL-C) levels. In this context, statins that are more effective in reducing TG levels, fibrates that can safely be combined with statins or fixed fibrate and statin combinations, as well as new, better tolerated nicotinic acid formulations might prove to be particularly beneficial.
Keywords: Triglyceride, statins, fibrates, nicotinic acid, cardiovascular disease, vascular risk
Current Drug Targets
Title: Triglycerides and Vascular Risk: Insights from Epidemiological Data and Interventional Studies
Volume: 10 Issue: 4
Author(s): Konstantinos Tziomalos, Vasilios G. Athyros, Asterios Karagiannis, Genovefa D. Kolovou and Dimitri P. Mikhailidis
Affiliation:
Keywords: Triglyceride, statins, fibrates, nicotinic acid, cardiovascular disease, vascular risk
Abstract: The role of elevated triglyceride (TG) levels in the pathogenesis of atherosclerosis is controversial. Some studies suggest that TG might play a direct role in the development of vascular disease. Elevated TG levels are also associated with other vascular risk factors and may therefore represent an indirect marker of a high risk state. Another issue is that laboratory measurements of TG levels frequently show a substantial variability. Accumulating epidemiological data show that there is an independent association of TG levels with vascular risk. Some interventional studies also suggested that lowering TG levels might prevent vascular events. It appears that TG might be more important as therapeutic targets against a background of optimal low density lipoprotein cholesterol (LDL-C) levels. In this context, statins that are more effective in reducing TG levels, fibrates that can safely be combined with statins or fixed fibrate and statin combinations, as well as new, better tolerated nicotinic acid formulations might prove to be particularly beneficial.
Export Options
About this article
Cite this article as:
Tziomalos Konstantinos, Athyros G. Vasilios, Karagiannis Asterios, Kolovou D. Genovefa and Mikhailidis P. Dimitri, Triglycerides and Vascular Risk: Insights from Epidemiological Data and Interventional Studies, Current Drug Targets 2009; 10 (4) . https://dx.doi.org/10.2174/138945009787846425
DOI https://dx.doi.org/10.2174/138945009787846425 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanisms of Action and Chemical-Biological Interactions Between Ozone and Body Compartments: A Critical Appraisal of the Different Administration Routes
Current Drug Therapy Diabetic Retinopathy: Current and New Treatment Options
Current Diabetes Reviews Automated Percutaneous Lumbar Discectomy for Symptomatic C ontained Disc Herniation: An Updated Review
Current Medical Imaging Anticoagulant Therapy During Pregnancy for Maternal and Fetal Acquired and Inherited Thrombophilia
Current Medicinal Chemistry Ethical and Social Issues in Pharmacogenomics Testing
Current Pharmaceutical Design Biochemical Aspects of Nitric Oxide
Current Pharmaceutical Design Low Osteopontin N-Terminal Fragment and Carotid Plaque Stability Associated with Statin or Antiplatelet Therapy
Current Vascular Pharmacology Molecular Targets of Diabetic Cardiovascular Complications
Current Drug Targets Issues and Progress in Isolation of Susceptibility Genes of Essential Hypertension
Current Hypertension Reviews Pathological Roles of Iron in Cardiovascular Disease
Current Drug Targets Peripheral Arterial Disease in Persons with Diabetic Foot Ulceration: a Current Comprehensive Overview
Current Diabetes Reviews PPARγ Agonists: Beneficial Effect on Blood Pressure Beyond Glycemic Control?
Current Hypertension Reviews Exploring Mode of Phosphoramidon and Aβ Peptide Binding to hECE-1 by Molecular Dynamics and Docking Studies
Protein & Peptide Letters Monocyte Adhesion in Atherosclerosis: A Biomechanical Approach
Vascular Disease Prevention (Discontinued) Hypersensitivity to Antineoplastic Agents
Current Pharmaceutical Design Oxidative Stress: Meeting Multiple Targets in Pathogenesis of Diabetic Nephropathy
Current Drug Targets Cardiac Metabolism in Diabetes Mellitus
Current Pharmaceutical Design Blood Coagulation as an Intrinsic Pathway for Proinflammation: A Mini Review
Inflammation & Allergy - Drug Targets (Discontinued) Long Chain n-3 Polyunsaturated Fatty Acids in the Prevention of Allergic and Cardiovascular Disease
Current Pharmaceutical Design Molecular and Clinical Aspects of the Target Therapy with the Calcimimetic Cinacalcet in the Treatment of Parathyroid Tumors
Current Cancer Drug Targets